48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse
Background and Aims. We aimed to ascertain the feasibility and safety of NA cessation, the status of patients after cessation, and the predictive factors for relapse and subsequent retreatment. Methods. A total of 92 patients were enrolled in this prospective study. Patients were monitored every mon...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2018/1817680 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564769680261120 |
|---|---|
| author | Wen-xiong Xu Qian Zhang Xiang Zhu Chao-shuang Lin You-ming Chen Hong Deng Yong-yu Mei Zhi-xin Zhao Dong-ying Xie Zhi-liang Gao Chan Xie Liang Peng |
| author_facet | Wen-xiong Xu Qian Zhang Xiang Zhu Chao-shuang Lin You-ming Chen Hong Deng Yong-yu Mei Zhi-xin Zhao Dong-ying Xie Zhi-liang Gao Chan Xie Liang Peng |
| author_sort | Wen-xiong Xu |
| collection | DOAJ |
| description | Background and Aims. We aimed to ascertain the feasibility and safety of NA cessation, the status of patients after cessation, and the predictive factors for relapse and subsequent retreatment. Methods. A total of 92 patients were enrolled in this prospective study. Patients were monitored every month for the first 3 months after cessation and every 3 months thereafter. Results. Sixty-two patients finished 48 weeks of follow-up. None died or developed liver failure, cirrhosis, or HCC. The 62 patients could be divided into 4 categories according to the 48-week clinical development of relapse. Virologic relapses occurred in 39 (62.9%) patients, with 72.7% occurring in the first 24 weeks in origin HBeAg positive patients and 82.4% in the first 12 weeks in origin HBeAg negative patients. Age (OR = 1.06, 95% CI = 1.02–1.10; p=0.003), the HBsAg level (OR = 2.21, 95% CI = 1.47–3.32; p<0.001), and positive origin HBeAg status (OR = 0.32, 95% CI = 0.14–0.74; p=0.008) were predictive factors to virologic relapse. HBV DNA level (OR = 1.34, 95% CI = 1.13–1.58; p<0.001) was predictive factor to retreatment. Conclusions. NA cessation is safe under supervision. Age, HBsAg level, and origin HBeAg status can be predictive factors for virologic relapse. The study was submitted to ClinicalTrials.gov Protocol Registration and Results System with the assigned NCT ID NCT02883647. |
| format | Article |
| id | doaj-art-9a97197e65d34900927f1b81f215ff10 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-9a97197e65d34900927f1b81f215ff102025-02-03T01:10:13ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972018-01-01201810.1155/2018/1817680181768048-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with RelapseWen-xiong Xu0Qian Zhang1Xiang Zhu2Chao-shuang Lin3You-ming Chen4Hong Deng5Yong-yu Mei6Zhi-xin Zhao7Dong-ying Xie8Zhi-liang Gao9Chan Xie10Liang Peng11Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, ChinaBackground and Aims. We aimed to ascertain the feasibility and safety of NA cessation, the status of patients after cessation, and the predictive factors for relapse and subsequent retreatment. Methods. A total of 92 patients were enrolled in this prospective study. Patients were monitored every month for the first 3 months after cessation and every 3 months thereafter. Results. Sixty-two patients finished 48 weeks of follow-up. None died or developed liver failure, cirrhosis, or HCC. The 62 patients could be divided into 4 categories according to the 48-week clinical development of relapse. Virologic relapses occurred in 39 (62.9%) patients, with 72.7% occurring in the first 24 weeks in origin HBeAg positive patients and 82.4% in the first 12 weeks in origin HBeAg negative patients. Age (OR = 1.06, 95% CI = 1.02–1.10; p=0.003), the HBsAg level (OR = 2.21, 95% CI = 1.47–3.32; p<0.001), and positive origin HBeAg status (OR = 0.32, 95% CI = 0.14–0.74; p=0.008) were predictive factors to virologic relapse. HBV DNA level (OR = 1.34, 95% CI = 1.13–1.58; p<0.001) was predictive factor to retreatment. Conclusions. NA cessation is safe under supervision. Age, HBsAg level, and origin HBeAg status can be predictive factors for virologic relapse. The study was submitted to ClinicalTrials.gov Protocol Registration and Results System with the assigned NCT ID NCT02883647.http://dx.doi.org/10.1155/2018/1817680 |
| spellingShingle | Wen-xiong Xu Qian Zhang Xiang Zhu Chao-shuang Lin You-ming Chen Hong Deng Yong-yu Mei Zhi-xin Zhao Dong-ying Xie Zhi-liang Gao Chan Xie Liang Peng 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse Canadian Journal of Gastroenterology and Hepatology |
| title | 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse |
| title_full | 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse |
| title_fullStr | 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse |
| title_full_unstemmed | 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse |
| title_short | 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse |
| title_sort | 48 week outcome after cessation of nucleos t ide analogue treatment in chronic hepatitis b patient and the associated factors with relapse |
| url | http://dx.doi.org/10.1155/2018/1817680 |
| work_keys_str_mv | AT wenxiongxu 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT qianzhang 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT xiangzhu 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT chaoshuanglin 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT youmingchen 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT hongdeng 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT yongyumei 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT zhixinzhao 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT dongyingxie 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT zhilianggao 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT chanxie 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse AT liangpeng 48weekoutcomeaftercessationofnucleostideanaloguetreatmentinchronichepatitisbpatientandtheassociatedfactorswithrelapse |